TNFRSF10B and neoplasm: As the resistance to TRAIL seems to exist in most tumor cells (33–35), the trials of newly developed anti-TRAIL-R2-drug conjugate reagents coupling with anti-miR-372 strategies could be elaborated as a potent therapeutic approach with the aim of ameliorating oncogenesis (34–36).